Cost-effectiveness of treatments for HER2-positive metastatic breast cancer and associated metastases: an overview of systematic reviews
- DOI
- 10.1080/14737167.2021.1848553
- Published
- 2020-12
- Container
- Expert Review of Pharmacoeconomics & Outcomes Research
- Publisher
- Informa UK Limited
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1080/14737167.2021.1848553,
title = {Cost-effectiveness of treatments for HER2-positive metastatic breast cancer and associated metastases: an overview of systematic reviews},
author = {Vakaramoko Diaby and Reem D. Almutairi and Aram Babcock and Richard K. Moussa and Askal Ali},
year = {2020},
journal = {Expert Review of Pharmacoeconomics \& Outcomes Research},
doi = {10.1080/14737167.2021.1848553},
url = {https://doi.org/10.1080/14737167.2021.1848553}
}RIS
TY - JOUR TI - Cost-effectiveness of treatments for HER2-positive metastatic breast cancer and associated metastases: an overview of systematic reviews AU - Vakaramoko Diaby AU - Reem D. Almutairi AU - Aram Babcock AU - Richard K. Moussa AU - Askal Ali PY - 2020 JO - Expert Review of Pharmacoeconomics & Outcomes Research DO - 10.1080/14737167.2021.1848553 UR - https://doi.org/10.1080/14737167.2021.1848553 ER -
APA
Diaby, V., Almutairi, R. D., Babcock, A., Moussa, R. K., & Ali, A. (2020). Cost-effectiveness of treatments for HER2-positive metastatic breast cancer and associated metastases: an overview of systematic reviews. Expert Review of Pharmacoeconomics & Outcomes Research. https://doi.org/10.1080/14737167.2021.1848553
Source records
- crossref · retrieved 2026-09-27T01:13:22.920Z